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The purpose of the work was to assess the predictive
value of biologic factors on the ef®cacy of highly
active antiretroviral therapy alone or combined with
chemotherapy on AIDS-associated Kaposi's sarcoma.
Twenty-six AIDS±Kaposi's sarcoma patients who
started therapy with protease inhibitors were investi-
gated. No baseline chemotherapy was associated
with less severe initial clinical status. Median follow-
up was 652 d. The main outcome measures were as
follows: best Kaposi's sarcoma clinical response;
Kaposi's-sarcoma-associated herpesviral load in per-
ipheral blood mononuclear cells using real-time
quantitative polymerase chain reaction (non-detect-
able if less than 100 copies per mg); human immuno-
de®ciency viral charge in plasma (non-detectable if
less than 200 copies per ml); and CD4 lymphocyte
count. Time to undetectable Kaposi's-sarcoma-asso-
ciated herpesviral load, time to undetectable human
immunode®ciency viral charge, and time to
CD4 > 150 per ml were also recorded over time,
from 2 mo measurements. Patients were staged
according to the AIDS Clinical Trials Group-based
tumor, immune, systemic staging system criteria. At
baseline, Kaposi's sarcoma was progressive for 25
(96%) of the 26 enrolled patients. Complete or par-
tial response to highly active antiretroviral therapy
alone or combined with chemotherapy was achieved
in 22 patients (85%). Median time to clinical
response was estimated at 251 d. Clinical response
was faster in patients without chemotherapy at
baseline (p = 0.003) as well as in patients not
previously treated with reverse transcriptase
inhibitors (p = 0.0012). Using univariable analyses,
predictive factors of clinical response were undetect-
able Kaposi's-sarcoma-associated herpesviremia
(p = 0.013), undetectable human immunode®ciency
viremia (p = 0.03), and relative variation of CD4
lymphocytes (p = 0.004). Using multivariable analy-
sis, undetectable Kaposi's-sarcoma-associated herpes-
viremia (p = 0.009) and relative variation of CD4
(p = 0.005) were independently selected as having a
predictive value for clinical response. Occurrence of
nondetection of either Kaposi's-sarcoma-associated
herpesvirus or human immunode®ciency virus was
not associated with baseline CD4 value. Kaposi's-sar-
coma-associated herpesvirus quantitative viral charge
is an independent predictive factor of the ef®cacy of
highly active antiretroviral therapy on AIDS±
Kaposi's sarcoma. Our results support immune
reconstitution as a mechanism of response of
Kaposi's sarcoma to highly active antiretroviral ther-
apy. Key words: highly active antiretroviral therapy/
Kaposi's sarcoma/KSHV viral load/predictive factors. J
Invest Dermatol 117:858±863, 2001
T
he reported incidence of Kaposi's sarcoma (KS), an
AIDS-de®ning disease, has dramatically decreased
since the advent of highly active antiretroviral therapy
(HAART). Reduction in incidence was recently
estimated at 38% per mo (Ledergerber et al, 1999).
This can be compared to the decreasing incidence of opportunistic
infections and opposed to the frequency of AIDS-associated non-
Hodgkin lymphoma, which has remained substantially unchanged
(Tirelli et al, 2000).
KS is associated with Kaposi's-sarcoma-associated herpesvirus
(KSHV) infection. Seroconversion for KSHV after HIV infection
was shown as strongly predictive of KS (Renwick et al, 1998). The
actual lower incidence of HIV-associated KS has been related to
HAART as KSHV seroprevalence has remained stable within the
last 20 y in homosexual populations, at least in Europe (Rezza et al,
2000). HAART has not only a preventive effect but also allows
remission of patent HIV-associated KS. Very few data are available,
however, concerning the clinical responses of KS to HAART
either alone or associated with conventional therapy: rate of
response, time to clinical response, as well as biologic parameters
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predictive of response. In order to explore these aspects further, we
set up a real-time quantitative polymerase chain reaction (PCR)
assay to measure KSHV viral load in the peripheral blood
mononuclear cells (PBMC). Indeed KSHV is mainly present in
cells and seldom detected in the plasma. We then monitored
prospectively CD4 counts, HIV viral load, and KSHV viral load in
PBMC in parallel with the clinical response in AIDS-associated KS
patients.
MATERIALS AND METHODS
Patient selection All consecutive patients in the two participating
centers with HIV-associated KS who started therapy with protease
inhibitors (PI) from April 1996 to September 1999 were included in this
study, provided (i) time to follow-up after PI institution was at least
equal to 3 mo, (ii) they had at least four measurable lesions with or
without lymphedema, (iii) they had stable or progressive KS, and (iv)
they had given their informed consent. Patients with visceral
involvement could be included. The study was approved by the ethical
committee of our hospital.
Patient evaluation Patients underwent a complete physical
examination monthly during 4 mo and every 2 mo thereafter, until a
stable response (see below) was obtained. Complete blood count
including CD4 lymphocytes, HIV viral charge in plasma, and KSHV
viral charge in PBMC was monitored every 2 mo. Patients were staged
according to the AIDS Clinical Trials Group-based (ACTG) tumor,
immune, systemic staging system (TIS) and were evaluated according to
the ACTG criteria (Krown et al, 1989, 1997).
Treatment plan All patients with AIDS-KS who entered the study
received at least two reverse transcriptase inhibitors (either nucleosidic or
not) and one PI. Simultaneous use of systemic chemotherapy with either
bleomycin, anthracyclins, or taxanes was allowed.
DNA extraction PBMC and, for some patients, cell-free plasma were
obtained from ethylenediamine tetraacetic acid (EDTA) blood specimens
after separation with Ficoll. After two washes with phosphate-buffered
saline, cells were pelleted and frozen at ±80°C until extraction. DNA
was extracted using QIAamp blood DNA extraction kit (Qiagen).
KSHV quantitative viral load DNA extracted from PBMC was ampli®ed
using real-time quantitative PCR performed on ABI Prism 7700 (Perkin
Elmer Applied Biosystems) in the presence of an internal probe within
open reading frame (ORF) 26 as described by Kennedy et al (1997),
synthesized, and dual labeled by Perkin Elmer (¯uorescent reporter dye
FAM at the 5¢ end and quencher dye TAMRA at the 3¢ end). The
primers 208 sense (5¢gtgctcgaatccaacggattt3¢) and 223 antisense
(5¢ccggccgatattttggagta3¢) amplifying a 116 bp fragment were chosen
using Primer Express Software (Perkin Elmer). No signi®cant homology
with any known human, bacterial, or viral nucleotide sequence was
found after extensive search in the EMBL and GenBank databases.
PCR was performed in 50 ml with a PCR core reagent: 10 pmol of
each primer, 10 pmol of probe, 1.25 U of AmpliTaqGold DNA
polymerase, 0.5 U of AmpErase uracile N-glycosylase, 200 mM of
dATP, dCTP, and dGTP, 400 mM of dUTP, 50 mM KCl, 5 mM
MgCl2, 10 mM Tris-HCl pH 8.3, 0.001% gelatin, and 500±1000 ng
DNA. Thermal cycling was initiated with 2 min of incubation at 50°C
followed by 10 min of denaturation at 95°C and 40 cycles of 95°C for
15 s and 60°C for 1 min. Dilutions of known amounts (10±107 copies)
of a fragment of KS330233 DNA (cloned in a plasmid) were used for the
standard curve. Plotting the cycle threshold values against given copy
numbers, we obtained a linear ampli®cation between 102 and 107 copies
with a coef®cient variation below 3%. A hundred copies was therefore
chosen as our cut-off value. Using these conditions, the ampli®cation
yield was equal to or greater than 85%.
DNA extracts were analyzed in duplicate. In each experiment distilled
water was used as control for cross-contamination. Negative control
specimens consisted of various non-KS skin biopsies (sarcoidosis n = 4,
lymphedema n = 1, angiosarcoma n = 3, normal skin n = 5), PBMC
from patients without KS (n = 10), and cell lines infected with other
herpesvirus (HSV1, HSV2, CMV, EBV, VZV, HHV6, and HHV7).
KSHV qualitative reverse transcriptase PCR (RT-PCR) in PBMC
extracts Qualitative reverse transcription for the late lytic spliced gene
ORF 29 was performed using primers described by Renne et al (1998)
located on opposite sides of the intron. In brief, RNA were isolated
using Trizol (Gibco BRL) according to the supplier's protocol. 1000 ng
RNA was reverse transcribed using 200 U of M-MLV Reverse
Transcriptase (Gibco BRL) in a total volume of 20 ml containing
500 mM of each dNTP (Gibco BRL), 50 units of ribonuclease inhibitor
(Amersham), and 120 pmol random hexanucleotide primers (Boehringer
Mannheim). One to 15 ml of cDNA was used for the PCR performed
in a total volume of 50 ml. The PCR mix contained 10 3 PCR Mg-
buffer, 20 pmol of each primer, and 1 unit of AmpliTaqDNA
polymerase; cDNA was ampli®ed during 42 cycles (30 s at 94°C, 1 min
at 58°C, and 1 min and 30 s at 72°C). Subsequent southern
hybridization was performed using two different 5¢-labeled speci®c
oligonucleotide probes located, respectively, at the 5¢ and 3¢ end of the
DNA sequence on opposite sides of the intron, named oligo 126,
TGTTGCGCACATCAGCGAGC, and oligo 127, TATAAGCTTGG-
CGTCTTTCT. Labelling of the 40 pmol of each probe (5 ml) was
performed using 5 ml [g-32P]-ATP (3000 Ci per mmol; 10 Ci per ml),
3 ml (30 UI) of T4 polynucleotide kinase (Gibco BRL), 5 ml of 5 3
exchange buffer (Gibco BRL), and 7 ml H20 for 30 min at 37°C
according to the manufacturer's instruction. Human b-actin ampli®cation
30 cycles (30 s at 94°C, 1 min at 58°C, and 2 min at 72°C) was used as
positive control for the presence of cDNA.
HIV viral load was determined in plasma using Roche Amplicor HIV-
1 Monitor Version 1.5 Roche-Diagnosis technique according to the
manufacturer's instruction. The lower limit of detection for the assay was
200 copies per ml [all specimens screened with the Quantiplex test
(Chiron, sensitivity 500 copies) before 1997 were retested using the
Roche Amplicor technique].
CD4 counts were monitored by ¯uorescence-activated cell sorter
analysis.
Statistical analysis Four endpoints were considered: clinical (either
partial or complete) response, time to occurrence of non-detectable
Table I. Description of the 26 enrolled AIDS-associated stable or progressive KS patients at baseline
Median (25th±75th percentiles) N (%)
Kaposi's sarcoma status
progressive
stable
Antiretroviral therapy
Protease inhibitors
Chemotherapy
CD4 (n = 25), /mm3
< 100
< 50
logHIV (n = 22), copies per ml
HIV < 200
KSHV (n = 9), copies per mg
25 (96%)
1 (4%)
16 (62%)
0
11(42%)
106 (34±159)
12 (46%)
8 (31%)
5.05 (4.22±5.3)
1 (4.5%)
13467 (7589±30154)
12 T0 (3 T0 I0 S0, 3 T0 I1 S0, 6 T0 I1 S1)
13 T1 (8 T1 I1 S1, 3 T1 I1 S0, 2 T1 I0 S1)1 T0 I0 S0
Bleomycin n = 1 (4%)
Liposomal anthracyclin n = 10(39%)
9/12 under RTa inhibitors
7/8 under RT inhibitors
1/1 under RT inhibitors
< 100 1(4%) 1/1 under RT inhibitors
aRT, reverse transcriptase.
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KSHV (< 100 copies per mg) and HIV (< 200 copies per ml) viral loads,
and time to occurrence of a CD4 count above 150 per mm3.
Time to each endpoint was estimated by the Kaplan±Meier method,
and then compared according to baseline characteristics by the log-rank
test. We also assessed the in¯uence over time on clinical response of
HIV and KSHV viral loads (after log transformation) and of CD4 cell
counts using either absolute and relative counts or the area under the
curve (AUC) of relative counts by use of the Cox model, in which these
variables were treated as time-dependent covariates. For better commu-
nication of results, the term AUC is replaced by ``evolution'' in the
results. The estimated hazard ratio (HR) was computed, with 95%
con®dence interval (95CI).
For continuous variables, median values with 25th and 75th percentiles
are reported.
All p-values were two-sided, with a type I error rate at 5%. Statistical
analyses were performed on SAS 6.12 (SAS, Cary, NC) software
package.
RESULTS
Patient characteristics at baseline A total of 26 patients
ful®lled the inclusion criteria. Characteristics at baseline of these 26
patients are summarized in Table I. Ten (38%) of the 26 patients
were naive from antiretroviral therapy whereas 16 (62%) had
previously received various combinations of antiretroviral therapy
excluding PI. Eleven were receiving chemotherapy (bleomycin n =
1, liposomal daunorubicin n = 10). No baseline chemotherapy was
associated with less severe initial clinical status. Most had severe
immunosuppression as median CD4 count was 106 per mm3, and
eight (32%) of 25 had less than 50 CD4 per mm3. Median HIV
viral load was 112,580 copies per ml with undetectable viral load in
only one (4%) of the 22 evaluated patients. KSHV viral load in
PBMC was performed within a median delay of 149 d (0±251 d)
with median value at 5384 copies per mg (100±12,185). KS was
progressive for 25 patients (96%) and stable for one patient.
Patient treatment over follow-up Median follow-up was 652
d (90±1329 d). During the study, all the patients received a
combination of two reverse transcriptase inhibitors and one PI.
Fifteen patients were also under chemotherapy. Treatments
received from baseline to best clinical response are detailed in
Table II. Eleven patients were free of chemotherapy or any speci®c
KS treatment during all the study period. Eleven patients were
under chemotherapy at baseline including daunorubicin (n = 10)
and bleomycin (n = 1), which had been stable during the past
4 wk. Of these patients, three remained under daunorubicin for
137, 329, and 335 d after enrollment, respectively. Seven patients
were switched from daunorubicin to docetaxel after a median time
of 314 d (184±711 d) after enrollment and were maintained under
this regimen until day 617 (226±780). Bleomycin, given at baseline
for one patient, was withdrawn at day 275. Finally, a speci®c
chemotherapy was introduced after enrollment for four patients,
including docetaxel (n = 1) from day 68 to day 383, daunorubicin
(n = 2) from day 68 to day 108 and day 30 to day 90, and
bleomycin (n = 1) from day 206 to day 395.
Clinical and biologic parameters predictive of clinical
response of KS Twenty-two (85%) of the 26 patients had
complete (n = 11) or partial (n = 11) response to antiviral therapy
alone or combined with chemotherapy, with a median time to
response estimated at 251 d. Among the four non-responders, two
had stable KS (time to follow-up, 153 and 466 d, respectively) and
two remained progressive, with uncontrolled HIV infection as
displayed by their HIV viral charge at 3,15 and 3,09 log; these two
patients had received antiretroviral therapy and chemotherapy
(docetaxel n = 1, etoposide n = 1). Of the 22 responders, only one,
who had achieved partial response after 393 d while on
antiretroviral therapy and chemotherapy (docetaxel), relapsed
with mild cutaneous lesions on day 840; chemotherapy had been
stopped at day 671.
Median time to clinical response was signi®cantly shortened for
patients free of chemotherapy at baseline (123 vs 314.5 d, p = 0.003
by the log-rank test), which can be related to less severe initial
status. As shown in Table III, clinical response was obtained faster
(median 123.5 d) for naive patients than for those previously
treated with inhibitors of reverse transcriptase (median 279 d) (p
= 0.0012 by the log-rank test). Similarly, times to reach a CD4
count above 150 per mm3 (median 73 d vs 329 d) (p = 0.009) and
to achieve a non-detectable HIV viral load of less than 200 copies
per ml (median 62 d vs 214.5 d) (p = 0.018) were signi®cantly
shorter in naive patients than in patients treated at baseline. Median
time to non-detection of KSHV viral load (< 100 copies per mg)
was shorter in the naive patients (median 180 d vs 307 d) although
the difference was not statistically signi®cant (p = 0.29 by the log-
rank test). Chemotherapy was associated with a longer time to
reach KSHV negative viremia (p = 0.02 by the log-rank test)
whereas no signi®cant difference was shown for the time to reach
HIV negative viremia (p = 0.09 by the log-rank test) and the time
to obtain > 150 CD4 count (p = 0.09 by the log-rank test)
(Table III).
Table IV reports the results of the univariable prognostic
analyses, assessing the in¯uence over time of occurrence of non-
detection of viral loads on the time to best clinical response. We
found that the occurrence of non-detectable KSHV viremia (p
= 0.013), non-detectable HIV viremia (p = 0.03), and CD4
evolution calculated by AUC-CD4 relative variation (but not
absolute CD4 value, nor CD4 levels above 150 per mm3 at baseline
or during follow-up) were predictive of clinical response. Using
multivariable analysis, the evolution of KSHV and CD4, calculated
using AUC of log KSHV and AUC-CD4 relative variations, were
independently selected as having a predictive value for clinical
response (Table IV).
Time to KSHV and HIV non-detection were similar whatever
the initial CD4 value below or greater than 150 per mm3
(respectively p = 0.72 and p = 0.53 by the log-rank test).
KSHV ORF 29 expression in PBMC In order to document
potential KSHV reactivation in PBMC in patients with progressive
KS we analyzed the expression of a late lytic gene involved in DNA
packaging. As recently published (Renne et al, 1998), ORF 29 gene
has a large intron that allows distinction between the spliced RT-
PCR product and contaminating genomic DNA. Eight patients
were tested. All but one were naive from antiretroviral therapy. All
had progressive KS and two received concomitant chemotherapy
that was initiated for one patient after the ®rst evaluation of ORF
29 expression. ORF 29 RT-PCR was negative for all specimens
Table II. Treatments received during the follow-up (from
baseline to best clinical response)a
Nb events/
Nb subjects
Median time
(95 CI), d
Protease inhibitors 26 140 (68±183)
IDV 20
NFV 2
RIT 1
SQV then IDV 1
RIT + SQV 1
RIT + IDV 1
Reverse transcriptase inhibitors 26 140 (68±183)
ZDV + 3TC 8
DDI + D4T 4
DDC + 3TC 1
D4T + 3TC 12
AZT + DDC 1
Chemotherapy 15 66 (0-NA)
Docetaxel 8
Bleomycin 2
Daunorubicin 12
aNA, not available; IDV, indinavir; NFV, nel®navir; RIT, ritonavir; SQV,
saquinavir; ZDV, zidovudine; DDI, didanosine; DDC, zalcitabine; 3TC, lamivu-
dine; D4T, stavudine; RT, reverse transcriptase.
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tested although b-actin control RT-PCR was positive. RNA
extracted from primary effusion cell lines and from patients' KS
tissues were positive, as shown in Fig 1.
DISCUSSION
In this study, we evaluated KS clinical response (complete and
partial response) to antiretroviral therapy either alone or associated
with chemotherapy in 26 AIDS-associated stable or progressive KS
patients. Such response was reached in 85% of patients within a
median time of 251 d. Improvement was stable during 652 d
(median follow-up). A similar response rate (74%) was previously
reported by Dupont et al (2000) after 24 mo follow-up in a series of
39 patients and on smaller groups of patients by ourselves (Lebbe et
al, 1998), Dupin et al (1999) and Cattelan et al (2001). Bower et al
(1999) stated that the median time to treatment failure for KS from
the start of HAART is 1.7 y compared to 0.5 y before HAART. In
our series, however, only one of the 22 responders had treatment
failure after a 732 d follow-up. We showed that the rise in CD4
value is predictive of clinical response as previously shown by us
and others (Lebbe et al, 1998; Dupont et al, 2000). Moreover, we
found that both CD4 rise and inability to detect HIV in the plasma
predicted good clinical responses. Before use of HAART, a CD4
level under 150 per mm3 was an independent prognostic factor of
HIV-associated KS occurrence (Miles et al, 1994; Hermans et al,
1997). In several large studies of HIV-infected patients under
HAART, decrease of plasma HIV RNA levels and increase of CD4
lymphocyte counts were strongly predictive of reduced risk of
subsequent opportunistic illness (Mellors et al, 1997; O'Brien et al,
1997; CheÃne et al, 1998; Ledergerber et al, 1999). CheÃne et al
(1998) showed that each 50% increase in CD4 cell count during
follow-up was associated with a 9% reduction of risk of
opportunistic illness. We did not ®nd that the CD4 count at the
time of initiation of antiretroviral therapy was predictive of a
delayed response, however, unlike the ®ndings of others with larger
cohorts of patients (Ledergerber et al, 1999; Miller et al, 1999). This
could be explained by a lack of power of our study, owing to the
small sample size. Our results suggest that immunologic changes
seem more important than absolute counts of immune and viral
parameters. Each patient could have an individual unique ``set
point'' of virologic and immunologic parameters that favor either
development or remission of KS. For instance, one of our patients
reached partial response for KS after the CD4 count rose from 26 to
200 per ml, whereas another one had progressive KS at baseline
Table IV. Predictive factors of clinical response, through
univariable (A) and multivariable analyses (B)a
HR (95CI); p-value
(likelihood ratio test)
(A) Univariable analyses
Covariate
KSHV < 100 copies per mcg 4.83 (1.40±16.7); p = 0.013
HIV < 200 copies per ml 2.77 (1.09±7.04); p = 0.03
CD4 > 150 per mm3 1.23 (0.51±2.95); p = 0.64
Evolution{log10 (KSHV)} 1.004 (1.001±1.006); p = 0.002
Evolution{log10 (HIV)} 1.001 (0.998±1.003); p = 0.22
Evolution{log10 (CD4)} 1.002 (0.998±1.006); p = 0.24
Evolution of relative CD4 (log10) 1.041 (1.013±1.069); p = 0.004
(B) multivariable analysis
Biologic factor
Evolution{log10 (KSHV)} 1.004 (1.001±1.006); p = 0.009
Evolution{log10 (HIV)} 1.002 (1.000±1.004); p = 0.10
Evolution of relative CD4 (log10) 1.007 (1.002±1.012); p = 0.005
ap-values in bold are considered as statistically signi®cant at the 5% level. As
mentioned in Materials and Methods, ``evolution'' has been assessed by calculating
the area under the curve for KSHV, HIV viral load, CD4 count, or relative CD4
(after log transformation). HR, hazard ratio; 95CI, 95% con®dence interval.
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with 274 CD4 count and reached partial response at 526 per ml
CD4.
Using real-time PCR, we showed that inability to detect KSHV
in PBMC was strongly predictive of clinical reponse, in multi-
variable analysis, to a greater extent than inability to detect HIV in
the plasma and CD4 increase. By contrast with Castleman's disease,
in KS, ¯uctuations of KSHV viral load in PBMC occurred as a rule
in the range 100±30,000 copies, which were undetectable by
semiquantitative PCR. Monitoring of KSHV viral load in PBMC
can thus only be done in a reliable fashion using quantitative PCR,
as classic PCR is too sensitive to allow monitoring of HIV-
associated KS. This high sensitivity probably explains apparent
discrepancies between our results and those of Nunez et al (2000).
Up to now, very few data are available in the literature, using either
competitive PCR (Lock et al, 1997; Boivin et al, 2000) or real-time
PCR (Lallemand et al, 2000; Little et al, 2000; Oksenhendler et al,
2000). The technique developed for this study is speci®c and allows
limited variations to be detected for amounts greater than or equal
to 100 copies per ml. Similar results were obtained by
Oksenhendler et al (2000) using the same probe but with primers
amplifying a different fragment from ORF 26, although linear
ampli®cation was observed over 30 copies. Lallemand et al (2000)
ampli®ed a fragment from ORF 73 and a cellular target (albumin
gene) in linear conditions from 10 to 106 copies.
The signi®cance of the correlation between KSHV viral load
reduction in PBMC and KS response is not univocal. Besides
spindle cells in KS specimens, several cell types have been shown to
harbour KSHV sequences, e.g., endothelial cells and monocytes
according to in situ hybridization or in situ PCR (Schulz, 1998). In
PBMC, CD19+ cells are the main reservoir, but KSHV sequences
can also occasionally be detected in T cells and monocytes. More
recently, Henry et al (1999) have demonstrated that CD34+
circulating cells, which could include hematopoietic stem cells but
also ®brocytes, progenitor endothelial cells, and KS spindle cells,
harbour the virus. Our results can be related to the disappearance of
KS spindle cells associated with the clinical remission. Therefore
KSHV viral load in PBMC can be paralleled to markers of residual
disease as usually developed in oncology. In fact we suggest that the
rise of KSHV viral load occurring in non-tumoral cells, mainly
B cells and monocytes, precedes the ¯are-up of the disease and that
KSHV reactivation could play a major role in KS by recruiting new
cell reservoirs. A link between ORF 65 (lytic gene) antibody levels,
but not LANA (latent gene) antibody levels, and KS tumor
extension favors this hypothesis (Cattelan et al, 2001). We are
planning to analyze KSHV viral load in separated B cells, T cells,
monocytes, and CD34+ potential KS spindle cell subpopulations
from PBMC.
In order to con®rm the hypothesis of KSHV reactivation related
to KS progression, we searched for the expression of a lytic gene
(ORF 29) in PBMC of several patients who had high viral load in
their PBMC. Using RT-PCR, however, we failed to detect any
expression. Such results can be compared with those from Babcock
et al (1999) on Epstein±Barr virus reactivation in post-transplant
patients. They showed that viral replication is frequently detected
in the blood of such immunosuppressed patients though no viral
gene expression was in evidence. Analyses of circular episomal
(latent virus) and linear forms (which correspond to lytic infection)
are planned for some of our patients using the technique developed
by Gardella et al (1984). We also intend to examine the presence of
KSHV sequences by PCR in cell-free plasma in order to detect
viral reactivation.
In conclusion, our data show that up to 85% of HIV-associated
KS have prolonged clinical responses to HAART alone or
combined with chemotherapy. We also showed that the inability
to detect KSHV in PBMC and the rise in CD4 count could predict
clinical response in multivariable analysis and thus could be used as
surrogate markers for clinicians, enabling them to discuss when
chemotherapy could be stopped for instance. KSHV viremia
¯uctuations raise questions about the potential role of KSHV
reactivation in KS pathology. Our results support immune
restitution as a mechanism of response of KS to HAART.
Moreover, very preliminary data suggest that KSHV-speci®c
immune recovery occurs during HAART in KS patients (Osman
et al, 1999). Other mechanisms can be hypothesized such as a direct
effect of HIV (via Tat for instance) on KSHV reactivation, which
has recently been demonstrated in vitro (Varthakavi et al, 1999).
This work was supported by ANRS, the Concerted Action: pathogenesis of AIDS
Kaposi's sarcoma (Biomed 2), and SIDACTION.
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